<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2601233183
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trodelvy
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SACITUZUMAB GOVITECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        180
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4836.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BSP PHARMACEUTICALS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BSP PHARMACEUTICALS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GILEAD SCIENCES LIMITED (CORK)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trodelvy is a cancer medicine that contains the active substance sacituzumab govitecan.</p><p>Trodelvy works by attaching to the cancer cells in your body. The medicine then enters the cancerous cells and kills them, thereby helping to fight your cancer.</p><p>&nbsp;</p><p>&nbsp;</p><p>Trodelvy (sacituzumab govitecan) is a prescription medicine used to treat adults with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a type of breast cancer called triple-negative breast cancer (TNBC), which is estrogen and progesterone hormone receptor (HR) negative, and human epidermal growth factor receptor 2 (HER2)-negative. Trodelvy may be used:</p><p>o&nbsp;&nbsp; when your breast cancer has spread to other parts of the body (metastatic) or cannot be removed by surgery, and</p><p>o&nbsp;&nbsp; if you previously received two or more prior treatments, including at least one treatment for metastatic disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a type of breast cancer that is HR-positive and HER2-negative. TRODELVY may be used:</p><p>o&nbsp;&nbsp; when your breast cancer has spread to other parts of the body or cannot be removed by surgery,</p><p><strong>and</strong></p><p>if you previously received endocrine therapy and at least two additional treatments for metastatic disease.</p><p>&nbsp;</p><p>It is not known if Trodelvy is safe and effective in people with moderate or severe liver problems.</p><p>It is not known if Trodelvy is safe and effective in children.</p><p>&nbsp;</p><p>Talk to your doctor or nurse if you have any questions about how Trodelvy works or why this medicine has been prescribed for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You<strong> <u>must not be given</u> </strong>Trodelvy<strong> </strong>if you are <strong>allergic</strong> to <strong>sacituzumab govitecan</strong> or any of the other <strong>ingredients</strong> of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p><strong><u>Seek urgent medical attention</u></strong> if you notice any of the following serious side effects whilst or after you are given Trodelvy:</p><p>&nbsp;</p><p><u>Infusion related reactions</u></p><p>These reactions can be severe and life-threatening and can emerge when receiving Trodelvy. <strong><u>Seek urgent medical attention</u></strong> if you have the following signs and symptoms of <strong>infusion related reactions</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden outbreak of swollen, pale red bumps or plaques (wheals) on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden attack of severe shivering accompanied by a feeling of coldness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulties and wheezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, heart palpitations.</p><p>You may be given some pre-infusion medicine by your doctor to help relieve the symptoms. During each infusion of the medicine and for 30 minutes after, you will be closely monitored for these signs and symptoms of infusion related reactions. Your doctor will slow down the infusion rate or stop it if you develop a serious infusion related reaction.</p><p>&nbsp;</p><p><u>Neutropenia</u></p><p>This medicine can cause neutropenia, a condition where you have too few neutrophils in your blood, resulting in increased risk of infections. These infections can be severe and life-threatening and may lead to death.<strong> <u>Seek urgent medical attention</u></strong> if you have the following signs and symptoms of <strong>neutropenia or infections</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a fever (a temperature of 38.5&deg;C or higher)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills or sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat, sores in the mouth, or a toothache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain near the anus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or burning when urinating, or urinating often</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea or sores around the anus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a cough or shortness of breath.</p><p>Your doctor will take blood samples to monitor neutrophils in your blood. You will not be given Trodelvy if the absolute neutrophil count is below a certain level on Day&nbsp;1 or Day&nbsp;8 of any cycle.</p><p>Your doctor will adjust the amount of medicine you are given if you have severe neutropenia.</p><p>&nbsp;</p><p><u>Diarrhoea</u></p><p><strong><u>Seek urgent medical attention</u></strong> if you suffer from severe <strong>diarrhoea</strong>, whilst receiving Trodelvy.</p><p>Your Trodelvy treatment will be postponed until your diarrhoea has improved.</p><p>You will be given loperamide to treat your diarrhoea, as long as you do not have an infection. If appropriate, you will also be given fluids.</p><p>Your doctor may also give you medicine, such as atropine, to help with stomach cramps, diarrhoea, and excessive saliva in mouth before your next treatment infusion.</p><p>Your diarrhoea can lead to dehydration and sudden kidney damage. Talk to your doctor if you experience dark-colored urine or decreased urine volume.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Nausea and vomiting</u></p><p>This medicine can cause nausea and vomiting. <strong><u>Seek urgent medical attention</u></strong> if you suffer from <strong>nausea or vomiting</strong> whilst receiving Trodelvy.</p><p>Your doctor will give you some medicines before your cancer therapy, and in between infusion sessions to help relieve nausea and vomiting. You will <strong>not be given</strong> Trodelvy if you <strong>have severe nausea and vomiting</strong> and will only be given Trodelvy when the symptoms have been controlled.</p><p>&nbsp;</p><p><u>Patients who have the UGT1A1*28 gene</u></p><p><u>&nbsp;</u></p><p>Some patients are more likely to have certain side effects from the medicine due to their genetic make-up. If you have the UGT1A1*28 gene, your body breaks the medicine down more slowly. This means you are more likely to develop certain side effects (such as neutropenia with or without fever and low level of red blood cells (anaemia)), than those who do not have the gene. These patients will be closely followed-up by their doctor.</p><p>&nbsp;</p><p><strong><u>Talk to your doctor or nurse before</u> you are given Trodelvy if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have kidney problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are a female and of child-bearing age (see &lsquo;Pregnancy, Breast-feeding and Fertility&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines to treat other conditions (see &lsquo;Other medicines and Trodelvy&rsquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have experienced any problems after receiving any infusions in the past.</p><p>&nbsp;</p><p>While you are being given Trodelvy, your doctor will monitor you closely for side effects. If you get any serious side effects, your doctor may give you other medicines to treat these side effects, may change how much Trodelvy you receive or may stop giving you Trodelvy altogether.</p><p>&nbsp;</p><p>See section&nbsp;4. for a list of all the side effects related to Trodelvy.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Trodelvy should not be given to children under 18 years old because there is no information about its use in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Trodelvy</strong></p><p>Tell your doctor if you are taking, have recently taken or might take <strong>any other medicines</strong>. Other medicines may affect the way Trodelvy works and may either raise the level of Trodelvy&rsquo;s active substance in your blood, increasing the risk of side effects. They are:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>propofol</strong>, given as an anesthetic in surgery.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ketoconazole</strong>, used to treat fungal infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tyrosine kinase inhibitors</strong> used to treat cancer (medicines ending in nib).</p><p>&nbsp;</p><p>Some medicines may lower the level of Trodelvy&rsquo;s active substance in your blood, decreasing its effects:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine</strong> or <strong>phenytoin</strong> used to treat epilepsy.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong> used to treat tuberculosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>protease inhibitor antivirals</strong> used to treat HIV.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Trodelvy <strong>should not be used</strong> during pregnancy because it may harm the baby. Tell your doctor immediately if you are pregnant, think you may be pregnant, or are planning to have a baby.</p><p>&nbsp;</p><p><strong>Male and female contraception</strong></p><p><strong>Women </strong>who might get pregnant <strong>must use effective contraception </strong>during treatment with Trodelvy, and for 6 months after the last dose of Trodelvy.</p><p><strong>Men</strong> with female partners who could become pregnant <strong>must use effective contraception</strong> during treatment and for 3 months after the last dose of Trodelvy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p><strong>Do not breast-feed </strong>during treatment and for 1 month after the last dose. It is unknown whether this medicine passes into breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Trodelvy may affect your ability to drive and use machines. You should therefore be cautious when driving, using tools or operating machines after being given Trodelvy</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trodelvy will only be given to you by your doctor or a nurse experienced in using anti-cancer therapies.</p><p>&nbsp;</p><p>It is important that the doctor specialising in your care has confirmed you can take this medicine by carrying out a blood test prior to treatment.</p><p>&nbsp;</p><p><u>Medicines given before Trodelvy treatment</u></p><p>You will be given some medicines before receiving Trodelvy to help stop infusion-related reactions and any nausea and vomiting. Your doctor will decide what medicines you may need and how much to take.</p><p>&nbsp;</p><p><u>How much you will be given</u></p><p>Treatment for your cancer is repeated in 21-day (3-week) cycles. The recommended dose is <strong>10&nbsp;mg for each kg of your body weight</strong> at the start of each cycle (Day 1 of each cycle) and again one week later (Day 8 of each cycle).</p><p>&nbsp;</p><p><u>How you will be given your medicine</u></p><p>A doctor or nurse will give the medicine via an intravenous infusion (a drip into your vein).</p><p><u>&nbsp;</u></p><p><strong>First infusion</strong>: you will be given your first infusion of medicine over 3&nbsp;hours.</p><p>&nbsp;</p><p><strong>Second and subsequent infusions:</strong> you will be given the other infusions over 1 to 2&nbsp;hours, if your first infusion was uneventful. Your doctor or nurse will monitor you during and 30 minutes after each infusion for signs and symptoms of infusion-related reactions.</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Your doctor will slow down the infusion rate of your medicine if you develop an infusion-related reaction. The medicine will be stopped if the infusion reaction is life-threatening. See section&nbsp;2.</p><p>&nbsp;</p><p><u>Dose of medicine when experiencing some side-effects</u></p><p>Your doctor may change or stop your dose if you experience certain side effects. See section&nbsp;4.</p><p>&nbsp;</p><p><strong>If you are given more Trodelvy than you should</strong></p><p>Since the infusion is given to you by your doctor or other appropriately trained staff, an overdose is unlikely. If you inadvertently receive too much medicine, your doctor will monitor you and give you additional treatment as required.</p><p><em>&nbsp;</em></p><p><strong>If a dose of Trodelvy is missed</strong></p><p>If you forget or miss your appointment, call your doctor or your treatment centre to make another appointment as soon as possible. Do not wait until your next planned visit. For the treatment to be fully effective, it is very important not to miss a dose.</p><p>&nbsp;</p><p><strong>If you stop treatment with Trodelvy</strong></p><p>You should not stop the therapy early without talking with your doctor first.</p><p>&nbsp;</p><p>The therapy for breast cancer with Trodelvy usually requires a number of treatments. The number of infusions that you receive will depend on how you are responding to treatment. Therefore, you should continue to take Trodelvy even if you see your symptoms improve until your doctor decides that Trodelvy should be stopped. If the treatment is stopped too early, your symptoms may return.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Serious side effects</strong></p><p><strong><u>Seek urgent medical attention</u></strong> if you get any of the following very common serious side effects <em>(may affect more than 1 in 10 people)</em>:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Low white blood cell count (neutropenia)</strong> which may cause the following signs and symptoms:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a fever, which is a temperature of 38.5&deg;C or higher: this is called <u>febrile neutropenia</u></p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills or sweating</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat, sores in the mouth, or a toothache</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain near the anus or sores around the anus</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or burning when urinating, or urinating often</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a cough or shortness of breath.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diarrhoea</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hypersensitivity reactions (including infusion-related reactions) </strong>which may cause the following signs and symptoms:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen lips, tongue, eyes, throat or face</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling or a raised, itchy, red skin rash</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outbreak of swollen, pale red bumps or plaques (wheals) on the skin that appear suddenly</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden attack of severe shivering accompanied by a feeling of coldness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wheezing, chest or throat tightness, shortness of breath, dizziness, feeling of fainting, breathlessness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, heart palpitations.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeling sick (nausea), being sick (vomiting)</strong></p><p>&nbsp;</p><p><strong>Other possible side effects</strong></p><p>Other side effects are listed below. If any of these become severe or serious, <u>tell your doctor immediately</u>.</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; burning sensation during urination and frequent, and urgent need to urinate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of enough red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of white blood cells (lymphocytes or leukocytes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood level of potassium or magnesium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased water in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath including shortness of breath when exercising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss; rash; general itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood level of phosphate</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shiver; fever; general discomfort; pale or discolored skin; shortness of breath due to overwhelmed bloodstream by bacteria (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the lungs (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blocked nose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat; runny nose; sneezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of platelets, which may lead to bleeding and bruising (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood level of glucose</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood level of calcium or sodium</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in your sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the small and large bowel (colitis) that may occur with a low white blood cell count (neutropenic colitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed and sore mouth; pain in upper stomach area; reflux; indigestion; bloated stomach</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; darkening of the skin; acne-like skin problem; dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excess protein in urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in an enzyme called alkaline phosphatase or lactate dehydrogenase, abnormal blood tests related to coagulation.</p><p>&nbsp;</p><p><strong>Uncommon </strong><em>(may affect up to 1 in 100 people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the small intestine (enteritis)</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the outer packaging after EXP. The expiry date refers to the last day of that month that the medicine can be used.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>After reconstituion and dilution, if not used immediately, the infusion bag containing diluted solution can be stored in a refrigerator (2&deg;C - 8&deg;C) for up to 24 hours protected from light.</p><p>&nbsp;</p><p>Do not use this medicine if you notice the reconstituted solution is cloudy or discoloured.</p><p>&nbsp;</p><p>Trodelvy is a cytotoxic drug. Applicable special handling and disposal procedures must be followed.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. The hospital pharmacist will throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is sacituzumab govitecan</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are 2-(<em>N</em>-morpholino)ethane sulfonic acid (MES), polysorbate 80 and trehalose dihydrate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	The medicine is an off-white to yellowish powder. It comes as 50 mL clear glass single-dose vials, with a rubber stopper and crimp-sealed with an aluminum flip-off cap. Each pack contains 1 vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Gilead Sciences, Inc.</p><p>333 Lakeside Drive,</p><p>Foster City, CA 94404</p><p>United States</p><p><strong>Final Batch Release Site</strong></p><p>Gilead Sciences Ireland UC</p><p>IDA Business &amp;&nbsp;Technology Park</p><p>Carrigtohill, Co. Cork</p><p>Ireland</p><p><strong>Bulk Manufacturer</strong></p><p>BSP Pharmaceuticals S.p.A.</p><p>Via Appia km 65,561</p><p>04013 Latina Scalo (LT)</p><p>Italy</p><p>&nbsp;</p><p><strong>To report any side effect(s): </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2023

SA-JUN2023-US-FEB2023-CCDS-SEP2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ترودلفي هو دواء للسرطان يحتوي على المادة الفعالة ساسيتوزوماب جوفيتيكان.</p><p dir="RTL">يعمل ترودلفي عن طريق الالتصاق بالخلايا السرطانية في جسمك. ثم يدخل الدواء إلى الخلايا السرطانية ويقتلها، مما يساعد على مكافحة حالة السرطان لديك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ترودلفي (ساسيتوزوماب جوفيتيكان) هو دواء يُصرف بوصفة طبية يُستخدم لعلاج البالغين المصابين بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من أنواع سرطان الثدي يسمى أيضًا سرطان الثدي الثلاثي السلبي حيث يكون مستقبل هرموني الإستروجين والبروجسترون (HR) سلبي، و مستقبل عامل نمو البشرة البشري 2 (HER2) سلبي. يمكن استخدام ترودلفي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما يكون سرطان الثدي قد انتشر إلى أجزاء أخرى من الجسم (نقيلي) أو لا يمكن إزالته عن طريق الجراحة، و</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت من قبل علاجين أو أكثر من العلاجات السابقة، بما في ذلك علاج واحد على الأقل لمرض السرطان المتقدم أو المنتشر (النقيلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من أنواع سرطان الثدي حيث يكون فيه (HR) موجباً و (HER2) سلبياً. يمكن استخدام ترودلفي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عندما يكون سرطان الثدي قد انتشر إلى أجزاء أخرى من الجسم&nbsp; أو لا يمكن إزالته عن طريق الجراحة، و</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت من قبل علاجاً للغدد الصماء بعلاج هرموني، وعلاجين إضافيين على الأقل لمرض السرطان النقيلي.</p><p>&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان ترودلفي آمنًا وفعالًا في علاج الأشخاص الذين يعانون من مشكلات متوسطة أو شديدة في الكبد.</p><p dir="RTL">من غير المعروف ما إذا كان ترودلفي آمنًا وفعالًا في علاج الأطفال.</p><p>&nbsp;</p><p dir="RTL">تحدث إلى طبيبك أو ممرضتك إذا كانت لديك أي أسئلة حول كيفية عمل ترودلفي أو سبب وصف هذا الدواء لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب<strong> <u>عدم تلقي</u> </strong>ترودلفي<strong> </strong>إذا كنت <strong>مصابًا بالحساسية</strong> تجاه <strong>ساسيتوزوماب جوفيتيكان</strong> أو أي مكون آخر <strong>من مكونات </strong>هذا الدواء (المدرجة في القسم 6). إذا كنت تعتقد أنك قد تكون مصابًا بالحساسية، فاستشر طبيبك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p>&nbsp;</p><p dir="RTL"><strong><u>اطلب العناية الطبية العاجلة</u></strong> إذا لاحظت أيًا من الآثار الجانبية الخطيرة التالية أثناء أو بعد تلقي ترودلفي:</p><p>&nbsp;</p><p dir="RTL"><u>التفاعلات المرتبطة بالتسريب</u></p><p dir="RTL">يمكن أن تكون هذه التفاعلات خطيرة ومهددة للحياة ويمكن أن تظهر عند تلقي ترودلفي. <strong><u>اطلب العناية الطبية العاجلة</u></strong> إذا أُصبت بالعلامات والأعراض التالية <strong>للتفاعلات المرتبطة بالتسريب</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار مفاجيء لنتوءات أو لويحات متورمة حمراء شاحبة (انتبار) على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة مفاجئة من الارتعاش الشديد مصحوبة بشعور بالبرودة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس والأزيز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر وخفقان القلب.</p><p dir="RTL">قد يعطيك طبيبك بعض أدوية ما قبل التسريب للمساعدة في تخفيف الأعراض. ستتم مراقبتك عن كثب بحثًا عن علامات وأعراض التفاعلات المرتبطة بالتسريب هذه خلال كل تسريب للدواء ولمدة 30 دقيقة بعد ذلك. سيقوم طبيبك بإبطاء معدل التسريب أو إيقافه إذا أُصبت بتفاعل خطير مرتبط بالتسريب.</p><p>&nbsp;</p><p dir="RTL"><u>قلة العدلات (نوع من كريات الدم البيضاء)</u></p><p dir="RTL">هذا الدواء قد يسبب لك أن يكون لديك عدد قليل جدًا من العدلات في دمك، مما يؤدي إلى زيادة خطر الإصابة بحالات العدوى . يمكن أن تكون حالات العدوى هذه شديدة ومهددة للحياة وقد تسبب الوفاة.<strong> <u>اطلب العناية الطبية العاجلة</u></strong> إذا أُصبت بالعلامات والأعراض التالية <strong>لقلة العدلات أو الالتهابات</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى (درجة حرارة قدرها 38.5 درجة مئوية أو أعلى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة أو التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق أو تقرحات في الفم أو ألم الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالقرب من فتحة الشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو حرقة عند التبول أو كثرة التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو التقرحات في محيط فتحة الشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال أو ضيق التنفس.</p><p dir="RTL">سيأخذ طبيبك عينات دم لمراقبة العدلات في دمك. لن تتلقى ترودلفي إذا كان عدد العدلات الكلي أقل من مستوى معين في اليوم الأول أو اليوم الثامن من أي دورة.</p><p dir="RTL">سيقوم طبيبك بتعديل كمية الدواء التي تتلقاها إذا أُصبت بقلة العدلات الشديدة.</p><p>&nbsp;</p><p dir="RTL"><u>الإسهال</u></p><p dir="RTL"><strong><u>اطلب العناية الطبية العاجلة</u></strong> إذا عانيت من <strong>إسهال</strong> شديد أثناء تلقيك ترودلفي.</p><p dir="RTL">سيتم تأجيل علاجك بترودلفي حتى تتحسن حالة الإسهال لديك.</p><p dir="RTL">سيتم إعطاؤك لوبراميد لعلاج الإسهال، ما دمت أنك لست مصابًا بعدوى. سيتم إعطاؤك سوائل أيضًا إذا كان ذلك ملائمًا.</p><p dir="RTL">قد يعطيك طبيبك أيضًا أدويةً، مثل أتروبين، للمساعدة في علاج تشنجات المعدة والإسهال واللعاب المفرط في الفم قبل تلقي تسريب العلاج التالي.</p><p dir="RTL">يمكن أن يؤدي الإسهال إلى الجفاف وتلف الكلى المفاجئ. تحدث إلى طبيبك إذا كنت تعاني من لون البول الداكن أو انخفاض كمية البول.</p><p>&nbsp;</p><p dir="RTL"><u>الغثيان والقيء</u></p><p dir="RTL">يمكن أن يسبب هذا الدواء الغثيان والقيء. <strong><u>اطلب العناية الطبية العاجلة</u></strong> إذا عانيت من <strong>غثيان وقيء</strong> أثناء تلقيك ترودلفي.</p><p dir="RTL">سيعطيك طبيبك بعض الأدوية قبل تلقي علاج السرطان وبين جلسات التسريب للمساعدة في تخفيف الغثيان والقيء. لن <strong>تتلقى</strong> ترودلفي إذا كنت <strong>مصابًا بغثيان وقيء شديدين</strong> وستتلقاه فقط بعد السيطرة على الأعراض.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">المرضى الذين لديهم جين UGT1A1 * 28</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المرجح أن يعاني بعض المرضى من آثار جانبية معينة من الدواء بسبب تركيبتهم الجينية. إذا كان لديك جين UGT1A1 * 28 ، فإن جسمك يكسر الدواء بشكل أبطأ. هذا يعني أنك أكثر عرضة للإصابة ببعض الآثار الجانبية (مثل قلة العدلات مع أو بدون حمى وانخفاض مستوى خلايا الدم الحمراء (فقر الدم)) ، من أولئك الذين ليس لديهم الجين. سيتم متابعة هؤلاء المرضى عن كثب من قبل الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>تحدث إلى طبيبك أو ممرضتك قبل</u> تلقي ترودلفي إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بمشكلات في الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بمشكلات في الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنتِ أنثى في سن الإنجاب (انظر &quot;الحمل والرضاعة الطبيعية والخصوبة&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية لعلاج حالات أخرى (انظر: &quot;الأدوية الأخرى وترودلفي&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد تعرضت لأي مشكلات بعد أي عمليات تسريب خضعت لها في الماضي.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">أثناء تلقي ترودلفي، سيراقبك طبيبك عن كثب بحثًا عن الآثار الجانبية. إذا أُصبت بأي آثار جانبية خطيرة، فقد يعطيك طبيبك أدوية أخرى لعلاج هذه الآثار الجانبية وقد يغير الكمية التي تتلقاها من ترودلفي أو قد يتوقف عن إعطائك ترودلفي تمامًا.</p><p>&nbsp;</p><p dir="RTL">انظر القسم 4. للحصول على قائمة بجميع الآثار الجانبية المرتبطة بترودلفي.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">ينبغي عدم إعطاء ترودلفي للأطفال تحت عمر 18 سنة نظرًا لعدم وجود معلومات حول استخدامه في هذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وترودلفي</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول <strong>أي أدوية أخرى</strong>. قد تؤثر الأدوية الأخرى على طريقة عمل ترودلفي وقد ترفع مستوى المادة الفعالة من ترودلفي في دمك، والذي قد يقود إلى زيادة خطر الآثار الجانبية. تلك الأدوية هي :</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بروبوفول</strong>، يُعطى كمخدر في الجراحة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كيتوكونازول</strong>، يُستخدم لعلاج حالات العدوى الفطرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مثبطات كيناز التيروزين</strong>، تُستخدم لعلاج السرطان (الأدوية المنتهية بـ&quot;نيب&quot;).</p><p dir="RTL">بعض الأدوية الأخرى قد تخفض مستوى المادة الفعالة من ترودلفي في دمك، مسببة تقليل فاعلية الدواء وهي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كاربامازيبين</strong> أو <strong>فينيتوين</strong>، يُستخدمان لعلاج الصرع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong>، يُستخدم لعلاج السل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مثبطات إنزيم البروتياز المضادة للفيروسات</strong>، تُستخدم لعلاج فيروس نقص المناعة البشرية (HIV).</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL"><strong>يجب عدم استخدام</strong> ترودلفي في حالة الحمل حيث أنه قد يسبب الضرر للجنين، أخبري طبيبك على الفور إذا كنت حاملاً، أو تعتقدين أنك قد تكونين حاملاً أو تخططين لإنجاب طفل.</p><p>&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل للذكور والإناث</strong></p><p dir="RTL"><strong>يجب على السيدات اللاتي قد يحملن استخدام وسائل منع حمل فعالة</strong> أثناء العلاج بترودلفي ولمدة 6 أشهر بعد آخر جرعة من ترودلفي.</p><p dir="RTL"><strong>يجب على الرجال الذين</strong> لديهم زوجات قد يحملن <strong>استخدام وسائل منع حمل فعالة</strong> أثناء العلاج ولمدة 3 أشهر بعد آخر جرعة من ترودلفي.</p><p>&nbsp;</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL"><strong>لا ترضعي رضاعةً طبيعية</strong> أثناء العلاج ولمدة شهر واحد بعد آخر جرعة. ليس معروفًا ما إذا كان يُفرز هذا الدواء في لبن الأم أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يؤثر ترودلفي على قدرتك على القيادة واستخدام الآلات. لذلك ينبغي أن تكون حذرًا عند القيادة أو استخدام الأدوات أو تشغيل الآلات بعد تلقي ترودلفي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لن يتم إعطاؤك ترودلفي إلا من قِبل طبيبك أو ممرضة من ذوي الخبرة في استخدام العلاجات المضادة للسرطان.</p><p>&nbsp;</p><p dir="RTL">من المهم أن يكون الطبيب المتخصص في رعايتك قد أكد أنه يمكنك تناول هذا الدواء من خلال إجراء فحص دم قبل العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>الأدوية التي يتم تلقيها قبل العلاج بترودلفي</u></p><p dir="RTL">سيتم إعطاؤك بعض الأدوية قبل تلقي ترودلفي للمساعدة في إيقاف التفاعلات المرتبطة بالتسريب وأي غثيان وقيء. سيقرر طبيبك الأدوية التي قد تحتاجها والكمية التي يجب أن تتناولها.</p><p>&nbsp;</p><p dir="RTL"><u>حجم الجرعة التي ستتلقاها</u></p><p dir="RTL">العلاج سيتم تكراره ضمن دورة علاجية مدتها 21 يوم (3أسابيع). الجرعة الموصى بها هي <strong>10 ملغ لكل كلغ من وزن الجسم</strong> في بداية كل دورة علاجية (اليوم الأول من كل دورة علاجية) ومرة أخرة بعد أسبوع (اليوم الثامن من كل دورة علاجية).</p><p>&nbsp;</p><p dir="RTL"><u>كيف ستتلقى دواءك</u></p><p dir="RTL">سيعطيك الطبيب أو الممرضة الدواء عن طريق التسريب الوريدي (بالتنقيط في الوريد).</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>التسريب الأول</strong>: ستتلقى أول تسريب من الدواء على مدار 3 ساعات.</p><p>&nbsp;</p><p dir="RTL"><strong>عمليات التسريب الثانية واللاحقة:</strong> ستخضع لعمليات التسريب الأخرى خلال ما يتراوح بين ساعة وساعتين، إذا كان التسريب الأول خاليًا من الحوادث. سيراقبك طبيبك أو الممرضة خلال التسريب ولمدة 30 دقيقة بعد كل تسريب وريدي للتحقق من عدم وجود مؤشرات أو أعراض للتفاعلات المرتبطة بالتسريب الوريدي.</p><p>&nbsp;</p><p dir="RTL"><u>التفاعلات المرتبطة بالتسريب</u></p><p dir="RTL">سيقوم طبيبك بإبطاء معدل تسريب دوائك إذا أُصبت بتفاعل مرتبط بالتسريب. سيتم إيقاف الدواء إذا كان تفاعل التسريب يهدد الحياة. انظر القسم 2.</p><p>&nbsp;</p><p dir="RTL"><u>جرعة الدواء التي يتم تناولها عند الإصابة ببعض الآثار الجانبية</u></p><p dir="RTL">قد يغير طبيبك الجرعة التي تتناولها أو يوقفها إذا أُصبت ببعض الآثار الجانبية. انظر القسم 4.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تلقيت جرعة من ترودلفي أكبر مما ينبغي</strong></p><p dir="RTL">نظرًا لأنك تتلقى التسريب من قِبل طبيبك أو غيره من أفراد فريق العمل المدربين تدريبًا ملائمًا، فمن غير المرجح أن يتم إعطاؤك جرعة زائدة. إذا تلقيت الكثير من الأدوية عن غير قصد، فسوف يراقبك طبيبك ويعطيك علاجًا إضافيًا حسب الحاجة.</p><p><em>&nbsp;</em></p><p dir="RTL"><strong>إذا تم تفويت جرعة من ترودلفي</strong></p><p dir="RTL">إذا نسيت موعدك أو فوّته، فاتصل بطبيبك أو بمركز العلاج الذي تذهب إليه لتحديد موعد آخر في أقرب وقت ممكن. لا تنتظر حتى الموعد المحدد لزيارتك القادمة. للحصول على الفعالية الكاملة للعلاج، من المهم جدًا عدم تفويت جرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن العلاج بترودلفي</strong></p><p dir="RTL">ينبغي ألا تُوقف العلاج في مرحلة مبكرة دون التحدث مع طبيبك أولًا.</p><p>&nbsp;</p><p dir="RTL">عادةً ما يتطلب علاج سرطان الثدي باستخدام ترودلفي تلقي عدد من العلاجات. ويعتمد عدد عمليات التسريب التي تخضع لها على مدى استجابتك للعلاج. لذلك، ينبغي أن تستمر في تناول ترودلفي حتى لو لاحظت تحسن الأعراض التي تعاني منها حتى يقرر طبيبك أنه ينبغي إيقاف ترودلفي. إذا تم إيقاف العلاج في مرحلة مبكرة للغاية، فقد تعود الأعراض.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع.</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong><u>اطلب العناية الطبية العاجلة</u></strong> إذا كنت تعاني من أي من الآثار الجانبية الشائعة جداً والخطيرة التالية (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انخفاض عدد خلايا الدم البيضاء (قلة العدلات)</strong> الذي قد يسبب العلامات والأعراض التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى، وهي ارتفاع درجة الحرارة إلى 38.5 درجة مئوية أو أعلى: وهو ما يُطلق عليه <u>قلة العدلات الحموية</u></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة أو التعرق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق أو تقرحات في الفم أو ألم الأسنان</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالقرب من فتحة الشرج أو تقرحات في محيط فتحة الشرج</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو حرقة عند التبول أو كثرة التبول</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال أو ضيق التنفس.</p><p>&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الإسهال</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات فرط الحساسية (بما في ذلك التفاعلات المرتبطة بالتسريب) </strong>التي قد تسبب العلامات والأعراض التالية:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الشفتين أو اللسان أو العينين أو الحلق أو الوجه</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ أو طفح جلدي أحمر مرتفع ومثير للحكة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار نتوءات أو لويحات متورمة حمراء شاحبة (انتبار) تظهر فجأة على الجلد</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة مفاجئة من الارتعاش الشديد مصحوبة بشعور بالبرودة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق المفرط</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزيز، ضيق الصدر أو الحلق، ضيق التنفس، الدوار وشعور بالإغماء، عسر التنفس.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر وخفقان القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الشعور بالغثيان، التقيؤ.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">الآثار الجانبية الأخرى مذكورة أدناه. إذا أصبحت أي من هذه الأعراض شديدًا أو خطيرًا، <u>فأخبر طبيبك على الفور</u>.</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>إحساس بالحرقة أثناء التبول والحاجة الملحة المتكررة للتبول</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>السعال والصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم البيضاء (الخلايا الليمفاوية أو الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم أو المغنيسيوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الماء في جسمك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس بما في ذلك ضيق التنفس عند ممارسة الرياضة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك وألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر، الطفح الجلدي، الحكة العامة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الفوسفات في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة، حمى، انزعاج عام، بشرة شاحبة أو متغيرة اللون، ضيق في التنفس بسبب مجرى الدم المليء بالبكتيريا (تعفن الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الرئتين (التهاب رئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق وسيلان الأنف والعطس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة لأعراض الإنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض نسبة الكالسيوم أو الصوديوم في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الدقيقة والغليظة (التهاب القولون) الذي قد يحدث مع انخفاض عدد خلايا الدم البيضاء (التهاب الأمعاء والقولون بقلة العَدِلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم وتقرحه، ألم في الجزء العلوي من المعدة، الإصابة بالارتجاع، عسر الهضم، انتفاخ المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسمرار الجلد، بثور في الجلد شبيهة بحب الشباب، جفاف الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة البروتين في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى إنزيم يسمى الفوسفاتاز القلوي أو نازعة هيدروجين اللاكتات، نتائج غير طبيعية لاختبارات الدم المتعلقة بالتخثر.</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الدقيقة (التهاب الأمعاء).</p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">الإبلاغ عن الآثار الجانبية</p><p dir="RTL">إذا أصبح أي من الآثار الجانبية خطيرًا أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، يرجى إخبار طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر الذي يمكن استخدام الدواء خلاله.</p><p>&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (في درجة حرارة من 2 إلى 8 درجات مئوية). لا تقم بتجميده.</p><p dir="RTL">احفظ القارورة في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p>&nbsp;</p><p dir="RTL">بعد التحضير والتخفيف، يمكن تخزين كيس التسريب الذي يحتوي على محلول مخفف في الثلاجة (في درجة حرارة من 2 إلى 8 درجات مئوية) لمدة تصل إلى 24 ساعة بعيدًا عن الضوء إذا لم يتم استخدامه على الفور.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أن المحلول المُحَضر مُعكَرًا أو بدا لونه متغيرًا.</p><p>&nbsp;</p><p dir="RTL">ترودلفي عقار سام للخلايا. ويجب اتباع الإجراءات الخاصة المُطبقة للتعامل مع الدواء والتخلص منه.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف. سيتخلص صيدلي المستشفى من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي ساسيتوزوماب جوفيتيكان</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي 2-( <em>ن</em>-مورفولينو) إيثان حمض السلفونيك (MES) وبولي سوربات 80 وتريهالوز ثنائي هيدرات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدواء عبارة عن مسحوق أبيض أو أبيض مائل للصفرة. ويأتي في صورة قوارير من الزجاج الشفاف سعة 50 مل تحتوي على جرعة أحادية، مع سدادة مطاطية وغطاء مطاطي مزود بقفل مُشكل بالضغط من الألومنيوم. تحتوي كل عبوة على قارورة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك ترخيص التسويق</strong></p><p dir="RTL">شركة جلعاد ساينسز</p><p dir="RTL">333 ليك سايد درايف،</p><p dir="RTL">فوستر سيتي، كاليفورنيا 94404</p><p dir="RTL">الولايات المتحدة</p><p dir="RTL"><strong>موقع إصدار الدُفعات النهائية</strong></p><p dir="RTL">جلعاد ساينسز أيرلندا يو سي</p><p dir="RTL">آي دي إيه بزنس أند تكنولوجي بارك</p><p dir="RTL">كاريغتوهيل، مقاطعة كورك،</p><p dir="RTL">أيرلندا</p><p dir="RTL"><strong>جهة التصنيع بالجملة</strong></p><p dir="RTL">بي إس بي فارماسيوتيكال ذات المسؤولية المحدودة</p><p dir="RTL">طريق أبيا كم 65561</p><p dir="RTL">04013 سكالو لاتينا (LT)</p><p dir="RTL">إيطاليا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2023

SA-JUN2023-US-FEB2023-CCDS-SEP2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TRODELVY® (sacituzumab govitecan) 180 mg powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 180 mg sacituzumab govitecan. After reconstitution, one mL of solution contains 10 mg sacituzumab govitecan.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Off-white to yellowish powder for concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Locally Advanced or Metastatic Breast Cancer</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH&ndash;) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Important use information</u></strong></p><p><strong>Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38. </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>The recommended dosage of TRODELVY is 10&nbsp;mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until disease progression or unacceptable toxicity. Do not administer TRODELVY at doses greater than 10 mg/kg.</p><p>&nbsp;</p><p><u>Premedication</u></p><p>Prior to each dose of TRODELVY, premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended.</p><p>&nbsp;</p><p><u>Dose modifications for infusion-related reactions</u></p><p>Slow or interrupt the infusion rate of TRODELVY if the patient develops an infusion-related reaction. Permanently discontinue TRODELVY for life-threatening infusion-related reactions (see section 4.4).</p><p>&nbsp;</p><p><u>Dose modifications for adverse reactions</u></p><p>Withhold or discontinue TRODELVY to manage adverse reactions as described in Table 1. Do not re-escalate the TRODELVY dose after a dose reduction for adverse reactions has been made.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Dose Modifications for Adverse Reactions </strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Occurrence</strong></p></td><td style="vertical-align:top"><p><strong>Dose Modification</strong></p></td></tr></thead><tbody><tr><td colspan="3"><p><strong>Severe Neutropenia </strong><em>[see section 4.4]</em></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Grade 4 neutropenia &ge;&nbsp;7 days,</p><p>OR</p><p>Grade 3-4 febrile neutropenia,</p><p>OR</p><p>At time of scheduled treatment, Grade 3-4 neutropenia which delays dosing by 2 or 3 weeks for recovery to &le;&nbsp;Grade 1</p></td><td style="vertical-align:top"><p>First</p></td><td style="vertical-align:top"><p>25% dose reduction and administer granulocyte-colony stimulating factor (G-CSF).</p></td></tr><tr><td style="vertical-align:top"><p>Second</p></td><td style="vertical-align:top"><p>50% dose reduction and administer G-CSF.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Third</p></td><td style="vertical-align:top"><p>Discontinue treatment and administer G-CSF.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>At time of scheduled treatment, Grade 3-4 neutropenia which delays dosing beyond 3&nbsp;weeks for recovery to &le;&nbsp;Grade 1</p></td><td style="vertical-align:top"><p>First</p></td><td style="vertical-align:top"><p>Discontinue treatment and administer G-CSF.</p></td></tr><tr><td colspan="3"><p><strong>Severe Non-Neutropenic Toxicity</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Grade 4 non-hematologic toxicity of any duration,</p><p>OR</p><p>Any Grade 3-4 nausea, vomiting or diarrhoea due to treatment that is not controlled with antiemetics and anti-diarrheal agents (see section 4.4)</p><p>OR</p><p>Other Grade 3-4 non-hematologic toxicity persisting &gt;&nbsp;48 hours despite optimal medical management,</p><p>OR</p><p>At time of scheduled treatment, Grade 3-4 non-neutropenic hematologic or non-hematologic toxicity, which delays dose by 2 or 3 weeks for recovery to &le;&nbsp;Grade 1</p></td><td style="vertical-align:top"><p>First</p></td><td style="vertical-align:top"><p>25% dose reduction</p></td></tr><tr><td style="vertical-align:top"><p>Second</p></td><td style="vertical-align:top"><p>50% dose reduction</p></td></tr><tr><td style="vertical-align:top"><p>Third</p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr><tr><td style="vertical-align:top"><p>In the event of Grade 3-4 non-neutropenic hematologic or non-hematologic toxicity, which does not recover to &le;Grade 1 within 3 weeks</p></td><td style="vertical-align:top"><p>First</p></td><td style="vertical-align:top"><p>Discontinue treatment</p></td></tr></tbody></table><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p><em><u>&nbsp;</u></em></p><p><em>Elderly</em></p><p>No dose adjustment is required in patients &ge; 65 years old. Data from sacituzumab govitecan in patients &ge; 75 years are limited.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No adjustment to the starting dose is required when administering TRODELVY to patients with mild hepatic impairment <em>[see section 5].</em></p><p>&nbsp;</p><p>The safety of TRODELVY in patients with moderate (total bilirubin &gt; 1.5 to 3.0 &times; ULN) or severe (total bilirubin &gt; 3.0 &times; upper limit of normal [ULN]) hepatic impairment has not been established. TRODELVY has not been tested in patients with AST or ALT &gt; 3 ULN without liver metastases, or AST or ALT &gt; 5 ULN with liver metastases. No recommendations can be made for the starting dose in these patients.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No adjustment to the starting dose is required when administering TRODELVY to patients with mild or moderate renal impairment.</p><p>TRODELVY has not been studied in patients with severe renal impairment or end-stage renal disease (Creatinine Clearance [CrCl] &lt; 15 mL/min).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of TRODELVY in children aged 0 to 18&nbsp;years have not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration </u></p><p>Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus.</p><p>&nbsp;</p><p>First infusion: Administer infusion over 3 hours. Observe patients during the infusion and for at least 30 minutes following the initial dose, for signs or symptoms of infusion-related reactions (see section 4.4).</p><p>&nbsp;</p><p>Subsequent infusions: Administer infusion over 1 to 2 hours if prior infusions were tolerated. Observe patients during the infusion and for at least 30 minutes after infusion.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TRODELVY is contraindicated in patients who have experienced a severe hypersensitivity reaction to TRODELVY (see section 4.4). 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neutropenia </u></p><p>Severe, life-threatening, or fatal neutropenia can occur in patients treated with TRODELVY. Neutropenia occurred in 64% of patients treated with TRODELVY. Grade 3-4 neutropenia occurred in 49% of patients. Febrile neutropenia occurred in 6% of patients. The median time to first onset of neutropenia (including febrile neutropenia) was 16 days and has occurred earlier in some patient populations. Neutropenic colitis occurred in 1.4% of patients.</p><p>&nbsp;</p><p>Withhold TRODELVY for absolute neutrophil count below 1500/mm<sup>3</sup> on Day 1 of any cycle or neutrophil count below 1000/mm<sup>3</sup> on Day 8 of any cycle. Withhold TRODELVY for neutropenic fever. Dose modifications may be required due to neutropenia. Administer G-CSF as clinically indicated or indicated in Table 1 (see sections 4.2 and 4.8).</p><p><u>&nbsp;</u></p><p><u>Diarrhoea</u></p><p>TRODELVY can cause severe diarrhea. Diarrhea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 diarrhea occurred in 11% of all patients treated with TRODELVY. One patient had intestinal perforation following diarrhea. Diarrhoea that led to dehydration and subsequent acute kidney injury occurred in 0.7% of all patients.</p><p>&nbsp;</p><p>Withhold TRODELVY for Grade 3-4 diarrhea at the time of scheduled treatment administration and resume when resolved to &le;Grade 1 (see section 4.2).<em> </em></p><p>&nbsp;</p><p>At the onset of diarrhea, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated.</p><p>&nbsp;</p><p>Patients who exhibit an excessive cholinergic response to treatment with TRODELVY (e.g., abdominal cramping, diarrhea, salivation, etc.) can receive appropriate premedication (e.g., atropine) for subsequent treatments.</p><p>&nbsp;</p><p><u>Hypersensitivity and Infusion-Related Reactions</u></p><p>Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with TRODELVY treatment. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions (see section 4.3).</p><p>&nbsp;</p><p>Hypersensitivity reactions within 24 hours of dosing occurred in 35% of patients treated with TRODELVY. Grade 3-4 hypersensitivity occurred in 2% of patients treated with TRODELVY. The incidence of hypersensitivity reactions leading to permanent discontinuation of TRODELVY was 0.2%. The incidence of anaphylactic reactions was 0.2%.</p><p>&nbsp;</p><p>Premedication for infusion reactions in patients receiving TRODELVY is recommended<em>. </em>Have medications and emergency equipment to treat infusion-related reactions, including anaphylaxis, available for immediate use when administering TRODELVY (see section 4.2).</p><p>&nbsp;</p><p>Closely monitor patients for hypersensitivity and infusion-related reactions during each TRODELVY infusion and for at least 30 minutes after completion of each infusion (see section 4.2).</p><p>&nbsp;</p><p>Permanently discontinue TRODELVY for Grade 4 infusion-related reactions (see section 4.2).</p><p><u>&nbsp;</u></p><p><u>Nausea and vomiting</u></p><p>TRODELVY is emetogenic. Nausea occurred in 64% of all patients treated with TRODELVY. Grade 3-4 nausea occurred in 3% of patients.</p><p>&nbsp;</p><p>Vomiting occurred in 35% of all patients treated with TRODELVY. Grade 3-4 vomiting occurred in 2% of these patients.</p><p>&nbsp;</p><p>Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV) (see section 4.2).</p><p>&nbsp;</p><p>Withhold TRODELVY doses for Grade 3 nausea or Grade 3-4 vomiting at the time of scheduled treatment administration and resume with additional supportive measures when resolved to &le;Grade 1 (see section 4.2).</p><p>&nbsp;</p><p>Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity </u></p><p>Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia; and may be at increased risk for other adverse reactions when treated with TRODELVY.</p><p>&nbsp;</p><p>The incidence of neutropenia and anemia was analyzed in 948 patients who received TRODELVY and had UGT1A1 genotype results. In patients homozygous for the UGT1A1 *28 allele (n=112), the incidence of Grade 3-4 neutropenia was 58%. In patients heterozygous for the UGT1A1*28 allele (n=420), the incidence of Grade 3-4 neutropenia was 49%. In patients homozygous for the wild-type allele (n=416), the incidence of Grade 3-4 neutropenia was 43% (see section 5.1). In patients homozygous for the UGT1A1 *28 allele, the incidence of Grade 3-4 anemia was 21%. In patients heterozygous for the UGT1A1*28 allele, the incidence of Grade 3-4 anemia was 10%. In patients homozygous for the wild-type allele, the incidence of Grade 3-4 anemia was 9%.</p><p>&nbsp;</p><p>The median time to first neutropenia including febrile neutropenia was 9 days in patients homozygous for the UGT1A1*28 allele, 15 days in patients heterozygous for the UGT1A1*28 allele, and 20 days in patients homozygous for the wild-type allele. The median time to first anemia was 21 days in patients homozygous for the UGT1A1*28 allele, 25 days in patients heterozygous for the UGT1A1*28 allele, and 28 days in patients homozygous for the wild-type allele.</p><p>&nbsp;</p><p>Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue TRODELVY based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 enzyme activity (see section 4.2).</p><p>&nbsp;</p><p><u>Embryo-Fetal Toxicity </u></p><p>Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells (see sections 5.1 and 5.3).<em> </em>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>UGT1A1 </u><u>inhibitors</u></p><p>Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38<em> </em>(see section 4.4 and sections 5.1 and 5.2). Avoid administering UGT1A1 inhibitors with TRODELVY.</p><p><u>UGT1A1 inducers</u></p><p>Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers<em> </em>(see section 4.4 and sections 5.1 and 5.2). Avoid administering UGT1A1 inducers with TRODELVY.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>Risk summary</em></p><p>Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. TRODELVY contains a genotoxic component, SN-38, and is toxic to rapidly dividing cells (see sections 5.1 and 5.3). Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 &ndash; 4% and 15 &ndash; 20%, respectively.</p><p><em>Animal data </em></p><p>There were no reproductive and developmental toxicology studies conducted with sacituzumab govitecan.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no information regarding the presence of sacituzumab govitecan or SN-38 in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose of TRODELVY.</p><p><u>&nbsp;</u></p><p><u>Women of childbearing potential </u></p><p>Verify the pregnancy status of females of reproductive potential prior to the initiation of TRODELVY.</p><p><u>&nbsp;</u></p><p><u>Contraception in males and females</u></p><p><em>Females </em></p><p>TRODELVY can cause fetal harm when administered to a pregnant woman (see section 4.6). Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose.</p><p><em>Males </em></p><p>Because of the potential for genotoxicity, advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.</p><p><u>Fertility</u></p><p>Based on findings in animals, TRODELVY may impair fertility in females of reproductive potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TRODELVY has minor influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1 Adverse reactions</strong></p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>The safety profile for TRODELVY as monotherapy is based on pooled data in 1063 patients across multiple tumor types, including patients with breast cancer who received TRODELVY 10 mg/kg. The median exposure to TRODELVY in this population was 4.1 months. Table 2 presents adverse reactions reported with TRODELVY. Frequency estimates include all reported adverse events for each listed adverse reaction.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Table&nbsp;2 presents adverse reactions reported with TRODELVY. Frequency estimates include all reported adverse events for each listed adverse reaction. Adverse reactions are listed by System Organ Class and frequency category. Frequency categories are defined as: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000) or not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in decreasing order of all severity grade frequencies.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><strong>2: List of adverse reactions in patients treated with Trodelvy</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top"><p><strong>All Grade </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Anemia<sup>2</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia<sup>3</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia<sup>4</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia<sup>5 </sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Stomatitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain upper</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distension</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastrooesophageal reflux disease</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Colitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenic colitis<sup>6</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Enteritis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions </strong></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>7</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity<sup>8</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations </strong></p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications </strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion related reaction</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood lactate dehydrogenase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Activated partial thromboplastin time prolonged</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphatemia</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dehydration</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea<sup>9</sup></p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rhinorrhoea</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue </strong></p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Very Common</p></td></tr><tr><td style="vertical-align:top"><p>Dry skin</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Rash maculo-papular</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin hyperpigmentation</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis acneiform</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p>1: Includes the following preferred terms: neutropenia; neutrophil count decreased.</p><p>2: Includes the following preferred terms: anemia; hemoglobin decreased; red blood cell count decreased.</p><p>3: Includes the following preferred terms: leukopenia; white blood cell count decreased.</p><p>4: Includes the following preferred terms: lymphopenia; lymphocyte count decreased.</p><p>5: Includes the following preferred terms: thrombocytopenia; platelet count decreased.</p><p>6: Includes the preferred term of neutropenic colitis and events reported as typhlitis.</p><p>7: Includes the following preferred terms: fatigue, asthenia.</p><p>8: Hypersensitivity events reported up to the end of the day after treatment was administered. Includes events coded to the following preferred terms: Cough; dyspnea; rash; pruritus; stomatitis; hypotension; rash maculopapular; flushing; erythema; chest discomfort; hypersensitivity; rhinitis allergic; wheezing; localized edema; dermatitis acneiform; conjunctivitis; rash pruritic; edema; rash macular; rash pustular; swelling; swelling face; urticaria; anaphylactic reaction; asthma; bronchospasm; conjunctivitis allergic; dermatitis; dermatitis contact; eye pruritus; mouth ulceration; periorbital edema; rash erythematous; scrotal edema; seasonal allergy; skin exfoliation; swollen tongue; tachypnoea; throat tightness; Type IV hypersensitivity reaction; choking.</p><p>9: &nbsp;Includes the following preferred terms: dyspnea; dyspnea exertional.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Immunogenicity</em></p><p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of TRODELVY.</p><p>During the median 4-month treatment period across clinical studies in patients treated with TRODELVY, 9 (1.1%) of 785 patients developed antibodies to sacituzumab govitecan; 6 of these patients (0.8% of all patients treated with TRODELVY) had neutralizing antibodies against sacituzumab govitecan. Because of the low occurrence of anti-drug antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of sacituzumab govitecan is unknown.</p><p><u>&nbsp;</u></p><p><u>To report any side effect(s):</u></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a clinical trial, planned doses of up to 18 mg/kg (approximately 1.8 times the maximum recommended dose of 10 mg/kg) of TRODELVY were administered. In these patients, a higher incidence of severe neutropenia was observed.</p><p>In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, in particular severe neutropenia, and appropriate treatment instituted.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, ATC code: L01FX17.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Sacituzumab govitecan is a Trop-2-directed antibody-drug conjugate. Sacituzumab is a humanized antibody that recognizes Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a linker. Pharmacology data suggest that sacituzumab govitecan binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death. Sacituzumab govitecan decreased tumor growth in mouse xenograft models of triple-negative breast cancer.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects </u></p><p><u>&nbsp;</u></p><p>The TRODELVY exposure-response relationships and pharmacodynamic time course for efficacy have not been fully characterized.</p><p>&nbsp;</p><p><em>Cardiac electrophysiology&nbsp; </em></p><p>The maximum mean change from baseline was 9.7 msec (the upper bound of the two-sided 90% confidence interval is 16.8 msec) at the recommended dose. A positive exposure-response relationship was observed between QTc increases and SN-38 concentrations.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><strong>&nbsp;</strong></p><p><strong>Locally Advanced or Metastatic Triple-Negative Breast Cancer</strong></p><p>&nbsp;</p><p><em>ASCENT</em></p><p>Efficacy was evaluated in a multicenter, open-label, randomized study (ASCENT; NCT02574455) conducted in 529 patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who had relapsed after at least two prior chemotherapies for breast cancer (one of which could be in the neoadjuvant or adjuvant setting provided progression occurred within a 12 month period). All patients received previous taxane treatment in either the adjuvant, neoadjuvant, or advanced stage unless there was a contraindication or intolerance to taxanes during or at the end of the first taxane cycle. Magnetic resonance imaging (MRI) to determine brain metastases was required prior to enrollment for patients with known or suspected brain metastases. Patients with brain metastases were allowed to enroll up to a pre-defined maximum of 15% of patients in the ASCENT study. Patients with known Gilbert&rsquo;s disease or bone-only disease were excluded.</p><p>&nbsp;</p><p>Patients were randomized (1:1) to receive TRODELVY 10 mg/kg as an intravenous infusion on Days 1 and 8 of a 21-day (n=267) or physician&rsquo;s choice of single agent chemotherapy (n=262). Single agent chemotherapy was determined by the investigator before randomization from one of the following choices: eribulin (n=139), capecitabine (n=33), gemcitabine (n=38), or vinorelbine (n=52).</p><p>&nbsp;</p><p>Patients were treated until disease progression or unacceptable toxicity. The major efficacy outcome was progression-free survival (PFS) in patients without brain metastases at baseline (i.e., BMNeg) as measured by a blinded, independent, centralized review assessed using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Additional efficacy measures included PFS for the full population (all patients with and without brain metastases) and overall survival (OS).</p><p>&nbsp;</p><p>The median age of patients in the full population (n = 529) was 54 years (range: 27 to 82 years); 99.6% were female; 79% were White, 12% were Black/African American; and 81% of patients were &lt; 65 years of age. All patients had an ECOG performance status of 0 (43%) or 1 (57%). Forty-two percent of patients had hepatic metastases, 9% were BRCA1/BRCA2 mutational status positive, and 70% were TNBC at diagnosis. Twelve percent had baseline brain metastases previously treated and stable (n=61; 32 on TRODELVY arm and 29 on single agent chemotherapy arm).</p><p>Overall, 29% of patients had received prior PD-1/PD-L1 therapy. Thirteen percent of patients in the TRODELVY group in the full population received only 1 prior line of systemic therapy in the metastatic setting.</p><p>&nbsp;</p><p>The efficacy results are summarized in Table 3 and are shown in Figure 1 and Figure 2. Efficacy results for the subgroup of patients who had received only 1 prior line of systemic therapy in the metastatic setting (in addition to having disease recurrence or progression within 12 months of neoadjuvant/adjuvant systemic therapy) were consistent with those who had received at least two prior lines in the metastatic setting.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 3: Efficacy Results from ASCENT </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:670px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>All Randomized Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>TRODELVY</strong></p><p><strong>n=267</strong></p></td><td style="vertical-align:top"><p><strong>Single Agent Chemotherapy</strong></p><p><strong>n=262</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression-Free Survival<sup>1</sup></strong><strong> </strong><strong>per BICR </strong></p></td></tr><tr><td style="vertical-align:top"><p>Disease Progression or Death (%)</p></td><td style="vertical-align:top"><p>190 (71%)</p></td><td colspan="2" style="vertical-align:top"><p>171 (65%)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS in months (95% CI)</p></td><td style="vertical-align:top"><p>4.8</p><p>(4.1, 5.8)</p></td><td colspan="2" style="vertical-align:top"><p>1.7</p><p>(1.5, 2.5)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>2</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.43 (0.35, 0.54)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Overall Survival </strong></p></td></tr><tr><td style="vertical-align:top"><p>Deaths (%)</p></td><td style="vertical-align:top"><p>179 (67%)</p></td><td colspan="2" style="vertical-align:top"><p>206 (79%)</p></td></tr><tr><td style="vertical-align:top"><p>Median OS in months (95% CI)</p></td><td style="vertical-align:top"><p>11.8</p><p>(10.5, 13.8)</p></td><td colspan="2" style="vertical-align:top"><p>6.9</p><p>(5.9, 7.6)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio<sup>2</sup> (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.51 (0.41, 0.62)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>1</sup><strong> </strong>PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.</p><p><strong><sup>2</sup></strong><strong> </strong>Stratified log-rank test adjusted for stratification factors: number of prior chemotherapies, presence of known brain metastases at study entry, and region.</p><p>CI = Confidence Interval</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure 1: Kaplan-Meier Plot of PFS by BICR (All Randomized Patients) in ASCENT </strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><img src="data:image/png;base64,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" alt="" width="605" height="286" vspace="0" hspace="0" border="0" style="width:605px;height:286px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure 2: Kaplan-Meier Plot of OS (All Randomized Patients) in ASCENT</strong></p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="605" height="285" vspace="0" hspace="0" border="0" style="width:605px;height:285px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>An exploratory analysis of PFS in patients with previously treated, stable brain metastases showed a stratified HR of 0.65 (95% CI: 0.35, 1.22). The median PFS in the TRODELVY arm was 2.8 months (95% CI: 1.5, 3.9) and the median PFS with single agent chemotherapy was 1.6 months (95% CI: 1.3, 2.9). Exploratory OS analysis in the same population showed a stratified HR of 0.87 (95% CI: 0.47, 1.63). The median OS in the TRODELVY arm was 6.8 months (95% CI: 4.7, 14.1) and the median OS with single agent chemotherapy was 7.4 months (95% CI: 4.7, 11.1).</p><p>&nbsp;</p><p><em>IMMU-132-01 </em></p><p>The efficacy of TRODELVY was evaluated in a multicenter, single-arm, study (NCT01631552) that enrolled 108 patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior anticancer therapies for metastatic disease. Patients with bulky disease, defined as a mass &gt;7 cm, were not eligible. Patients with treated brain metastases not receiving high dose steroids (&gt;20 mg prednisone or equivalent) for at least four weeks were eligible. Patients with known Gilbert&rsquo;s disease were excluded.</p><p>&nbsp;</p><p>Patients received TRODELVY 10 mg/kg intravenously on Days 1 and 8 of a 21-day treatment cycle. Patients were treated with TRODELVY until disease progression or intolerance to the therapy. Tumor imaging was obtained every 8 weeks, with confirmatory CT/MRI scans obtained 4-6 weeks after an initial partial or complete response, until progression requiring treatment discontinuation. Major efficacy outcome measures were investigator assessed overall response rate (ORR) using RECIST 1.1 and duration of response.</p><p>&nbsp;</p><p>The median age was 55 years (range: 31 to 80 years); 87% of patients were younger than 65 years. The majority of patients were female (99%) and White (76%). At study entry, all patients had an ECOG performance status of 0 (29%) or 1 (71%). Seventy-six percent had visceral disease, 42% had hepatic metastases, 56% had lung/pleura metastases, and 2% had brain metastases. Twelve patients (11%) had Stage IV disease at the time of initial diagnosis.</p><p>&nbsp;</p><p>The median number of prior systemic therapies received in the metastatic setting was 3 (range: 2 to 10). Prior chemotherapies in the metastatic setting included carboplatin or cisplatin (69%), gemcitabine (55%), paclitaxel or docetaxel (53%), capecitabine (51%), eribulin (45%), doxorubicin (24%), vinorelbine (16%), cyclophosphamide (19%), and ixabepilone (8%).</p><p>&nbsp;</p><p>Overall, 98% of patients had received prior taxanes and 86% had received prior anthracyclines either in the (neo)adjuvant or metastatic setting.</p><p>&nbsp;</p><p>Table 4 summarizes the efficacy results.</p><p><strong>Table 4: Efficacy results for patients with mTNBC in IMMU-132-01</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>TRODELVY</p><p>(N&nbsp;=&nbsp;108)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Response Rate<sup>i</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)</p></td><td style="vertical-align:top"><p>33.3% (24.6, 43.1)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response</p></td><td style="vertical-align:top"><p>2.8%</p></td></tr><tr><td style="vertical-align:top"><p>Partial response</p></td><td style="vertical-align:top"><p>30.6%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Duration of response<sup>i</sup></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>36</p></td></tr><tr><td style="vertical-align:top"><p>Median, Months (95% CI)</p></td><td style="vertical-align:top"><p>7.7 (4.9, 10.8)</p></td></tr><tr><td style="vertical-align:top"><p>Range, Months</p></td><td style="vertical-align:top"><p>1.9<sup>+</sup>, 30.4<sup>+</sup></p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;6&nbsp;months</p></td><td style="vertical-align:top"><p>55.6%</p></td></tr><tr><td style="vertical-align:top"><p>% with duration &ge;&nbsp;12&nbsp;months</p></td><td style="vertical-align:top"><p>16.7%</p></td></tr></tbody></table><p>CI: confidence interval</p><p><sup>i</sup>investigator assessment</p><p>+: denotes ongoing</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer</strong></p><p>&nbsp;</p><p><em>TROPiCS-02 Study</em></p><p>&nbsp;</p><p>The efficacy of TRODELVY was evaluated in a multicenter, open label, randomized study (TROPiCS-02; NCT03901339) conducted in 543 patients with unresectable locally advanced or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH&ndash;) breast cancer whose disease has progressed after the following in any setting: a CDK 4/6 inhibitor, endocrine therapy, and a taxane; patients received at least two prior chemotherapies in the metastatic setting (one of which could be in the neoadjuvant or adjuvant setting if recurrence occurred within 12 months).</p><p>&nbsp;</p><p>Patients were randomized (1:1) to receive TRODELVY 10 mg/kg as an intravenous infusion on Days 1 and 8 of a 21 day cycle (n=272) or single agent chemotherapy (n=271). Single agent chemotherapy was determined by the investigator before randomization from one of the following choices: eribulin (n=130), vinorelbine (n=63), gemcitabine (n=56), or capecitabine (n=22).&nbsp; Randomization was stratified by the following factors: prior chemotherapy regimens for metastatic disease (2 vs. 3-4), visceral metastasis (Yes or No), and endocrine therapy in the metastatic setting for at least 6 months (Yes or No).</p><p>&nbsp;</p><p>Patients were treated until disease progression or unacceptable toxicity. Administration of TRODELVY was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. The primary efficacy outcome measure was PFS as determined by BICR per RECIST v1.1. Additional efficacy measures included OS, ORR by BICR, and DOR by BICR.</p><p>The median age of patients in the study population was 56 years (range: 27&ndash;86 years), 26% of patients were 65 years or over. The majority of patients were female (99%); 67% were White, 4% were Black and 3% were Asian, and 26% were of unknown race. Patients received a median of 7 (range: 3 to 17) prior systemic regimens in any setting and 3 (range: 0 to 8) prior systemic chemotherapy regimens in the metastatic setting. Approximately 42% of patients had 2 prior chemotherapy regimens for treatment of metastatic disease compared to 58% of patients who had 3 to 4 prior chemotherapy regimens and all patients had an ECOG performance status of 0 (45%) or 1 (55%). Ninety-five percent of patients had visceral metastases. Most patients received endocrine therapy in the metastatic setting for &sup3; 6 months (86%).</p><p>TRODELVY demonstrated a statistically significant improvement in PFS and OS versus single agent chemotherapy.</p><p>The efficacy results are summarized in Table 5 and Figure 3 and Figure 4.</p><p><strong>Table 5: Efficacy Results from TROPiCS-02</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>All Randomized Patients</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>TRODELVY</strong></p><p><strong>n=272</strong></p></td><td style="vertical-align:top"><p><strong>Single Agent Chemotherapy</strong></p><p><strong>n=271</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Progression-Free Survival by BICR<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Median PFS in months</p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>5.5</p><p>(4.2, 7.0)</p></td><td style="vertical-align:top"><p>4.0</p><p>(3.1, 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>0.661 (0.529, 0.826)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.0003</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Overall Survival<sup>3 </sup></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Median OS in months</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>14.4</p><p>(13.0, 15.7)</p></td><td style="vertical-align:top"><p>11.2</p><p>(10.1, 12.7)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.789 (0.646, 0.964)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>p-value<sup>2</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0200</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Objective Response Rate<sup>3</sup> by BICR</strong></p></td></tr><tr><td style="vertical-align:top"><p>Response Rate, % (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>21.0 (16.3, 26.3)</p></td><td style="vertical-align:top"><p>14.0 (10.1, 18.7)</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio (95% CI)</p></td><td colspan="3" style="vertical-align:top"><p>1.625 (1.034, 2.555)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="3" style="vertical-align:top"><p>0.0348</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Duration of Response<sup>3</sup> (DOR) by BICR</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median DOR in months</p><p>(95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>8.1</p><p>(6.7, 9.1)</p></td><td style="vertical-align:top"><p>5.6</p><p>(3.8, 7.9)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><sup>1 </sup></strong>PFS is defined as the time from the date of randomization to the date of the first radiological disease progression or death due to any cause, whichever comes first.</p><p><sup>2</sup> Stratified log-rank test adjusted for stratification factors: prior chemotherapy regimens for metastatic disease (2 vs. 3-4), visceral metastasis (Y/N), and endocrine therapy in the metastatic setting for at least 6 months (Yes or No).</p><p>BICR = Blinded Independent Central Review; CI = Confidence Interval</p><p><sup>3 </sup>Second interim OS analysis (conducted when 390 OS events were observed)</p><p><strong>Figure 3: Kaplan-Meier Plot of PFS by BICR in TROPiCS-02</strong></p><p><img src="data:image/png;base64,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" alt="" width="605" height="361" vspace="0" hspace="0" border="0" style="width:605px;height:361px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><strong>&nbsp;</strong></p><p><strong>Figure 4: Kaplan-Meier Plot of OS in TROPiCS-02</strong></p><p><strong><sup>&nbsp;<img src="data:image/png;base64,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" alt="" width="918" height="544" vspace="0" hspace="0" border="0" style="width:918px;height:544px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></sup></strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The serum pharmacokinetics of sacituzumab govitecan and SN-38 were evaluated in patients with mBC who received sacituzumab govitecan as a single agent at a dose of 10&nbsp;mg/kg. The pharmacokinetic parameters of sacituzumab govitecan and free SN-38 are presented in Table&nbsp;6.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 6: Summary of Mean PK Parameters (CV%) of sacituzumab govitecan and Free SN-38</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Sacituzumab govitecan</strong></p><p><strong>(N=693)</strong></p></td><td style="vertical-align:top"><p><strong>Free SN-38</strong></p><p><strong>(N=681)</strong></p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> [ng/mL]</p></td><td style="vertical-align:top"><p>239000 (11%)</p></td><td style="vertical-align:top"><p>98.0 (45%)</p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-168 </sub>[ng*h/mL]</p></td><td style="vertical-align:top"><p>5640000 (22%)</p></td><td style="vertical-align:top"><p>3696 (56%)</p></td></tr></tbody></table><p><sup>*</sup>Parameters estimated based on population PK analyses</p><p>C<sub>max</sub>: maximum serum concentration from 0-168 hours after the first dose</p><p>AUC<sub>0-168</sub>: area under serum concentration curve through 168&nbsp;hours after the first dose</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Based on population pharmacokinetic analysis, steady state volume of distribution of sacituzumab govetican is 3.6 L.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>The median elimination half-life of sacituzumab govitecan half-life (t<sub>1/2</sub>) and free SN-38 in patients with metastatic triple negative breast cancer was 23.4 and 17.6&nbsp;hours, respectively. Based on population pharmacokinetic analysis, the estimated mean (%CV) clearance of the sacituzumab govitecan is 0.13 L/h (12%).</p><p>&nbsp;</p><p><u>Metabolism</u></p><p>No metabolism studies with sacituzumab govitecan have been conducted. SN-38 (the small molecule moiety of sacituzumab govitecan) is metabolized via UGT1A1. The glucuronide metabolite of SN-38 (SN-38G) was detectable in the serum of patients. Genetic variants of the UGT1A1 gene such as the UGT1A1*28 allele lead to reduced UGT1A1 enzyme activity. Individuals who are homozygous or heterozygous for the UGT1A1*28 allele are potentially at increased risk for neutropenia, febrile neutropenia, and anaemia from TRODELVY compared to individuals who are wildtype (*1/*1)<em>.</em> Approximately 20% of the Black or African American population, 10% of the White population, and 2% of the East Asian population are homozygous for the UGT1A1*28 allele (*28/*28). Approximately 40% of the Black or African American population, 50% of the White population, and 25% of the East Asian population are heterozygous for the UGT1A1*28 allele (*1/*28). Decreased function alleles other than UGT1A1*28 may be present in certain populations.</p><p><u>&nbsp;</u></p><p><u>Special Populations</u></p><p>Pharmacokinetic analyses in patients treated with TRODELVY did not identify an effect of age (27 to 88 years), race (White, Black, or Asian), or mild renal impairment to moderate renal impairment (CLcr 30 to 89 mL/min) on the pharmacokinetics of sacituzumab govitecan. Renal elimination is known to contribute minimally to the excretion of SN-38, the small molecule moiety of sacituzumab govitecan. There are no data on the pharmacokinetics of sacituzumab govitecan in patients with severe renal impairment (CLcr 15 to 29 mL/min), or end-stage renal disease (CLcr &lt; 15 mL/min).</p><p>&nbsp;</p><p><em>Patients with Hepatic impairment</em></p><p>The exposure of sacituzumab govitecan is similar in patients with mild hepatic impairment (bilirubin &le;ULN and AST &gt; ULN, or bilirubin &gt;1.0 to &le;1.5 ULN and AST of any level; n=257) to patients with normal hepatic function (total bilirubin or AST &le; ULN; n=526).</p><p>Sacituzumab govitecan and free SN-38 exposures are unknown in patients with moderate (total bilirubin &gt; 1.5 to 3.0 &times; ULN) or severe (total bilirubin &gt; 3.0 &times; ULN) hepatic impairment.</p><p>&nbsp;</p><p><u>Drug Interaction Studies </u></p><p>No drug-drug interaction studies were conducted with sacituzumab govitecan or its components. Inhibitors or inducers of UGT1A1 may increase or decrease SN-38 exposure, respectively (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity studies have not been conducted with sacituzumab govitecan.</p><p>SN-38 was clastogenic in an <em>in vitro </em>mammalian cell micronucleus test in Chinese hamster ovary cells and was not mutagenic in an <em>in vitro </em>bacterial reverse mutation (Ames) assay.</p><p>Fertility studies with sacituzumab govitecan have not been conducted. In a repeat-dose toxicity study in cynomolgus monkeys, intravenous administration of sacituzumab govitecan on Day 1 and Day 4 resulted in endometrial atrophy, uterine hemorrhage, increased follicular atresia of the ovary, and atrophy of vaginal epithelial cells at doses &ge;60 mg/kg (&ge; 6 times the human recommended dose of 10 mg/kg based on body weight).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2-(<em>N</em>-morpholino)ethane sulfonic acid (MES)</p><p>Polysorbate 80</p><p>Trehalose dihydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial
3 years
After reconstitution
The reconstituted solution should be used immediately to prepare the diluted solution for infusion. If not used immediately, the infusion bag containing diluted solution can be stored in a refrigerator (2°C to 8°C) for up to 24 hours protected from light.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C-8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I colorless, clear glass 50 mL vial, with an elastomeric butyl stopper and sealed with an aluminum flip-off overseal.</p><p>Each pack contains one vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TRODELVY is a cytotoxic drug. Applicable special handling and disposal procedures have to be followed.</p><p>&nbsp;</p><p><u>Reconstitution</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the required dose (mg) of TRODELVY based on the patient&rsquo;s body weight at the beginning of each treatment cycle (or more frequently if the patient&rsquo;s body weight changed by more than 10% since the previous administration).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow the required number of vials to warm to room temperature.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Using a sterile syringe, slowly inject 20&nbsp;mL of sodium chloride 0.9% solution for injection, into each 180&nbsp;mg TRODELVY vial. The resulting concentration will be 10&nbsp;mg/mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gently swirl vials and allow to dissolve for up to 15&nbsp;minutes. Do not shake. The product should be inspected visually for particulate matter and discoloration prior to administration. The solution should be free of visible particulates, clear and yellow. Do not use the reconstituted solution if it is cloudy or discoloured.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use immediately to prepare a diluted TRODELVY solution for infusion.</p><p>&nbsp;</p><p><u>Dilution</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the required volume of the reconstituted TRODELVY solution needed to obtain the appropriate dose according to patient&rsquo;s body weight. Withdraw this amount from the vial(s) using a syringe. Discard any unused portion remaining in the vial(s).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjust the volume in the infusion bag as needed with sodium chloride 0.9% solution for injection, to obtain a concentration of 1.1&nbsp;mg/mL to 3.4&nbsp;mg/mL (the total volume should not exceed 500&nbsp;mL). For patients whose body weight exceeds 170&nbsp;kg, divide the total dosage of TRODELVY equally between two 500&nbsp;mL infusion bags and infuse sequentially via slow infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slowly inject the required volume of reconstituted TRODELVY solution into a polyvinyl chloride, polypropylene, or polypropylene copolymer infusion bag to minimise foaming. Do not shake the contents.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only sodium chloride 0.9% solution for injection should be used since the stability of the reconstituted product has not been determined with other infusion-based solutions. Use the diluted solution in the infusion bag immediately. If not used immediately, the infusion bag containing TRODELVY solution can be stored refrigerated at 2&deg;C to 8&deg;C for up to 24&nbsp;hours protected from light. After refrigeration, administer diluted solution at room temperature up to 25&deg;C within 8&nbsp;hours (including infusion time).</p><p>&nbsp;</p><p>Do not freeze or shake. Protect from light.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer TRODELVY as an intravenous infusion. Protect infusion bag from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An infusion pump may be used.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not mix TRODELVY, or administer as an infusion, with other medicinal products.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upon completion of the infusion, flush the intravenous line with 20&nbsp;mL sodium chloride 0.9% solution for injection.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences, Inc.
333 Lakeside Drive,
Foster City, CA 94404
United States

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2023

SA-JUN2023-US-FEB2023-CCDS-SEP2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>